As the outcomes for breast cancer continue to improve and patients are surviving longer, the morbidity of treatments has become more apparent. The timing and type of surgery both have huge impacts on the systemic therapies and radiation for which a patient is eligible.
Additionally, we continue to learn more about the heterogeneity of breast cancer tumor biology and further understand that different cancer subtypes require dramatically different treatments. Therefore, a multidisciplinary approach to management in the preoperative setting is important to ensure optimal treatments and outcomes. New technologies also are providing exciting potential to further minimize surgical morbidity.
This article examines the importance of a multidisciplinary approach to breast cancer treatment, developments in axillary management, oncoplastic techniques, and emerging technologies such as robotic nipple-sparing mastectomy and tumor ablation.
Comentários